Please login to the form below

Not currently logged in
Email:
Password:

Lupin

This page shows the latest Lupin news and features for those working in and with pharma, biotech and healthcare.

India denies Vertex patent on cystic fibrosis drug Orkambi

India denies Vertex patent on cystic fibrosis drug Orkambi

The patent was opposed by the Indian Pharmaceutical Alliance (IPA), a trade organisation representing India's larger pharmaceutical companies, including Cipla, Dr Reddy's Labs, Lupin, Nicholas Piramal, Ranbaxy and Wockhardt.

Latest news

More from news
Approximately 1 fully matching, plus 22 partially matching documents found.

Latest Intelligence

  • Deal Watch August 2016 Deal Watch August 2016

    165. Shionogi (JP). Kyowa (JP) (Lupin). Asset acquisition Japan. 21 branded products in Japan with $90m sales.

  • Pharma deals in July 2015 Pharma deals in July 2015

    The consolidation in the generics industry has also increased with Lupin's acquisition of the US generics company Gavis for $880m at a high sales multiple of nine but which has ... In July Lupin also acquired a factory in Russia and a speciality product

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Minoyrx Therapeutics appoints chief medical officer Minoyrx Therapeutics appoints chief medical officer

    Dr Uwe Meya joins from Lupin Atlantis Holdings. Spanish orphan disease specialist Minoryx Therapeutics has appointed Dr Uwe Meya as its new chief medical officer. ... He joins the Barcelona-based drug development company from Lupin Atlantis Holdings,

  • Lupin appoints Thierry Volle president for EMEA Lupin appoints Thierry Volle president for EMEA

    He moves to the company from Vifor. Mumbai-based pharma company Lupin has appointed Thierry Volle to lead its Europe, Middle-East and Africa operations as president. ... Vinita Gupta, Lupin's chief executive officer, said: "We are delighted to have

  • Dr Maurice Chagnaud appointed as new CEO of Polpharma Dr Maurice Chagnaud appointed as new CEO of Polpharma

    He will join the company next week from Lupin where he was a group president with an inhalation remit for Europe, Russia &CIS. ... We are impressed by the extensive experience of Mr Chagnaud, gained in international companies such as Merck Generics, Teva

  • Lupin names chief corporate development officer Lupin names chief corporate development officer

    Theresa Stevens has experience at Novartis and Aptalis. Lupin has appointed Theresa Stevens as chief corporate development officer for its global operations. ... Lupin's decision to hire Stevens follows its appointment earlier this year of Teva's Dr

  • Lupin appoints European president Lupin appoints European president

    countries. He will also be responsible for developing Lupin's core strategy for inhalation across all developed markets. ... Prior to joining Lupin, Dr Chagnaud was senior VP, Central and Eastern Europe, at Israel-based Teva.

More from appointments
Approximately 3 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics